Notwithstanding the remarkable success in treating patients in CML-CP with ABL kinase inhibitors such as imatinib [2], [3], some patients acquire resistance or intolerance to ABL kinase inhibitors, culminating in disease progression from CML-CP to the accelerated phase (AP) and BC [1], [3], [4]. Here, ABL1 is linked to breast cancer.